title: Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
abstract: Measurement of endogenous thrombin potential (ETP) detects hypercoagulability and can be used to identify activated protein C resistance due to factor V Leiden (FVL). However, not all carriers of FVL suffer thrombosis and therefore we sought to determine if the test for ETP could be modified in such a way as to enable detection of FVL patients who were at increased risk of venous thromboembolism. Protac, an activator of both protein C and factor V, was incorporated into the traditional thrombin generation reaction and ratios (reaction with Protac:reaction without Protac) were calculated. Plasma samples from 42 FVL heterozygotes (12 with a history of thrombosis and 30 with no prior thrombosis) and 38 controls (non-FVL with no history of thrombosis) were analysed. The mean ETP ratio was significantly higher in FVL heterozygotes (0.90 +/- 0.06) compared to normal controls (0.41 +/- 0.10; p = 0.00004). Multivariate analysis indicated that the average ETP ratio was significantly and inversely correlated with factor V levels in FVL heterozygotes (p = 0.002) but not controls. Within the FVL group, patients with a history of thrombosis had higher ETP ratios (0.92 +/- 0.06) compared to those without (0.89 +/- 0.05), however, this did not reach statistical significance (p = 0.09). Further investigation into the use of ETP for detecting risk of thrombosis in people who are genetically predisposed is warranted. The recent introduction of diagnostic ETP measurements in the form of the calibrated automated thrombin generation from Thrombinoscope and the TechnoThrombin from Baxter should facilitate such studies.
authors.affiliation: Hunter Haematology Research Group, Newcastle Mater Misericordiae Hospital, Waratah, Australia. Lisa.Lincz@newcastle.edu.au
authors.forename: Lisa F
authors.initials: LF
authors.lastname: Lincz
authors.forename: Amy
authors.initials: A
authors.lastname: Lonergan
authors.forename: Fiona E
authors.initials: FE
authors.lastname: Scorgie
authors.forename: Phillip
authors.initials: P
authors.lastname: Rowlings
authors.forename: Richard
authors.initials: R
authors.lastname: Gibson
authors.forename: Andrew
authors.initials: A
authors.lastname: Lawrie
authors.forename: Michael
authors.initials: M
authors.lastname: Seldon
mesh_terms: D000328:Adult; D000368:Aged; D005165:Factor V / Q000032:analysis* / Q000737:chemistry / Q000235:genetics; D005260:Female; D006579:Heterozygote; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000737:chemistry; D011486:Protein C / Q000032:analysis* / Q000737:chemistry; D012307:Risk Factors; D013917:Thrombin / Q000032:analysis* / Q000737:chemistry; D013918:Thrombin Time; D013923:Thromboembolism / Q000097:blood* / Q000235:genetics; D019851:Thrombophilia / Q000097:blood* / Q000235:genetics
chemical_list: D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D011486:Protein C; C095381:factor V Leiden; C049647:snake venom protein C activator; D005165:Factor V; D013917:Thrombin